New data presented at the Crohn’s Disease and Colitis Conference 2023 in Denver show that the herbal compounds curcumin and QingDai are superior to placebo to induce clinical response and remission in patients with ulcerative colitis. suggesting.
In a multicenter trial, Israeli researchers found promising results for a treatment called CurQD by week 8, and using curcumin alone for an additional 8 weeks, even in the absence of new safety signals. We found that the majority of patients responded well.
The two-part study included a 4-week open-label study and a placebo-controlled study in 2 centers in Israel and Greece.
This study is a step forward from previous studies that showed that this therapy was effective in treating patients with mild to moderate and moderate to severe ulcerative colitis. Results show that 70% (n = 7) of patients responded, including 30% (n = 3) of his who achieved clinical remission.
In the second part, primary outcomes of clinical response and objective evidence of response were achieved in 43% of patients treated with CurQD, compared to only 8% in the placebo group.
in an interview with HCP Live®Shomron Ben-Horin, M.D., Sheba Medical Center, Tel Hashomer, and Nir Salomon, co-founder and head of R&D at Evinature, said encouraging results suggest there is room for herbal medicines to treat ulcerative colitis. It is shown that.
